### 1 Direct and ultrasensitive bioluminescent detection of intact respiratory viruses

- 2
- 3 Alexander Gräwe<sup>1</sup>, Harm van der Veer<sup>1</sup>, Seino A.K. Jongkees<sup>2</sup>, Jacky Flipse<sup>3,4</sup>, Iebe Rossey<sup>5</sup>,
- 4 Robert P. de Vries<sup>6</sup>, Xavier Saelens<sup>5</sup>, Maarten Merkx<sup>1\*</sup>
- 5

24

25

- 1 Laboratory of Protein Engineering, Department of Biomedical Engineering and Institute for Complex
   Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands. E-mail:
- 8 m.merkx@tue.nl
- 9 2 Department of Chemistry and Pharmaceutical Sciences, Amsterdam Institute of Molecular and Life
- 10 Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- 11 3 Laboratory for Medical Microbiology and Immunology, Rijnstate Hospital, Arnhem, The Netherlands
- 12 4 Laboratory for Medical Microbiology and Immunology, Dicoon, Elst, the Netherlands
- 5 VIB Center for Medical Biotechnology, Department of Biochemistry and Microbiology, Ghent University,
   Ghent, Belgium
- 6 Utrecht Institute for Pharmaceutical Sciences, Department of Chemical Biology and Drug Discovery,
   Utrecht, The Netherlands
- 16 Utrecht, The Netherla
- 18 \*Corresponding author: Maarten Merkx, <u>m.merkx@tue.nl</u>

### 20 Supporting Information

# This PDF file includes:

- Figures S1 to S12
- Section S1 Supplementary Materials and Methods
- 26 Section S2 Protein Sequences 27





#### 31 Figure S1.

#### 32 GLOVID without binders attached.

LgBiT-Dog1 and SmBiT-Dog1 were mixed and used in titrations agains soluble, trimeric viral
 surface protein H1Sol (H1 from A/Solomon Islands/3/2006 (H1N1). Experimental conditions:
 5 nM LgBiT-Dog1, 5 nM SmBiT-Dog1, final NanoGlo dilution 1:1000, 1 h incubation 22 °C. Error

36 bars represent the standard deviation of n=3 replicates.

37 38



- 39
- 40 Figure S2.

#### 41 Trivalent GLOVID with F-VHH-4.

42 GLOVID with anti-prefusion RSV-F nanobody F-VHH-4 conjugated to LgBiT-Dog3 and SmBiT-

43 Dog3 (trivalent system). Experimental conditions: 1 nM GLOVID components, 1xPBS + 1mg/ml

44 BSA, final NanoGlo dilution 1:2000, 1 h incubation 22 °C. The mean of n=3 replicates is shown,

45 with error bars too small to be depicted.





#### 49 Figure S3.

#### 50 Trivalent GLOVID and control on H3HK with S5.

a) Trivalent GLOVID where cyclic peptide S5 was conjugated to each LgBiT-Dog3 and SmBiTDog3 and used in titrations of H1Sol. b) Control GLOVID on H3HK with cyclic peptide S5
conjugated to both sensor components. Experimental conditions: 2 nM LgBiT, 6 nM SmBiT,
1xPBS, 1 h incubation at 22 °C, 1:1000 diluted NanoGlo. Error bars represent the standard
deviation of n=3 replicates.





#### 58 Figure S4.

#### 59 MST of scFv variants targeting RSV-G

60 Microscale thermophoresis (MST) experiments for anti-RSV-G scFv versions of 3G12 and 2D10.

61 A final concentration of Alexa647-labelled scFvs of 2 nM was used, with 60% excitation power

and 40% MST power. MST on anti-N2 AS4C-HL-DogTag was previously described in (1). Shown

are traces from single experiments.



#### 66 Figure S5.

#### 67 Monovalent GLOVID with 1GO1 scFv

68 GLOVID assays with scFv binder 1GO1 conjugated to LgBiT-Dog1 and SmBiT-Dog1, targeting

69 IAV N1/09. Experimental conditions: final GLOVID component concentration 2 nM, 1xPBS + 1 70 mg/ml BSA, 16 h incubation at 4 °C, final NanoGlo dilution 1:2000. Error bars represent the

71 standard deviation of n=3 replicates.

72





#### 76 Controls of anti RSV-G GLOVID (1/2)

GLOVID on RSV-G B1 assay using a combination of 3G12-LgBiT and 2D10-SmBiT.
 Experimental conditions: 1xPBS plus 1 mg/ml BSA, 2 nM each sensor component, 1 h incubation

at 22 °C, 1:2000 diluted NanoGlo substrate. The mean of n=3 replicates is shown, with error bars too small to be depicted.





#### 83 Figure S7.

#### 84 Controls of anti RSV-G GLOVID (2/2)

65 GLOVID on RSV-G A2 using the same scFv (3G12 or 2D10) on both sensor components.

86 Experimental conditions: 1xPBS plus 1 mg/ml BSA, 4 nM each sensor component, incubation 4

°C for 16 h to reach full binding equilibrium, 1:2000 diluted NanoGlo substrate. Error bars represent
 the standard deviation of n=3 replicates.









#### **RT-qPCR standard curves** 93

Standard curves of RT-qPCR on H1N2 (GeneXpert Flu/SARS/RSV triplex plus) and RSV-A2 94

(Seegene RV essential). The dashed line corresponds to the LoD of the H1N2 GLOVID (Ct 28.86); 95

S9

the dotted line corresponds to the LoD of the RSV-A2 GLOVID (Ct 23.27). Data points represent 96

97 single measurements from a dilution series of H1N2 or RSV-A2, respectively.

98







#### 108 GLOVID assays targeting RSV-A2 via one surface protein.

a) GLOVID assay that uses F-VHH-4 as binder, in monovalent fashion (F-VHH-4 fused to LgBiT-

110 Dog1 and SmBiT-Dog1) and trivalent fashion (F-VHH-4 fused to LgBiT-Dog3 and SmBiT-Dog3);

b) GLOVID assay that uses 3G12 (fused to LgBiT-Dog1) and 2D10 (fused to SmBiT-Dog1) as

sensor parts. Experimental conditions: 4 nM final GLOVID component concentration, 1xPBS, final

NanoGlo dilution 1:2000, 2 h incubation 22 °C. Error bars represent the standard deviation of n=3
 replicates.





#### 118 **Figure S10.**

#### 119 Spiking experiments in different matrices.

Spiking experiment where virus (RSV-A2) was added to different matrices (FastAmp (Intact Genomics), 1xPBS, 15% diluted nasal swab) and tested with GLOVID via F-VHH-4-LgBiT / F-

Genomics), 1xPBS, 15% diluted nasal swab) and tested with GLOVID via F-VHH-4-LgBiT / F-VHH-4-SmBiT (a) or 2D10-LgBiT / F-VHH-4-SmBiT (b). Experimental conditions: 3 nM LgBiT,

6 nM SmBiT, buffer as indicated in the legend, final NanoGlo dilution 1:1000, 1 h incubation at 22

<sup>124</sup> °C. Error bars represent the standard deviation of n=3 replicates.



Figure S11.

## 128 Analytical HPLC trace of purified final S5-dog tag product.

129 The purification was performed on a C18 column, with an elution gradient 27.5-47.5% v/v

acetonitrile in water with 0.1% trifluoroacetic acid.



### 134 **Figure S12.**

#### 135 Mass spectrum of HPLC peak at retention time 19.9 min (Figure S13).

136 Calculated for final product  $C_{255}H_{364}N_{70}O_{74}S$ : 5622.66, found 804.7 (calc. for  $[M+7H]^{7+}$ : 804.2),

137 938.6 (calc. for  $[M+6H]^{6+}$ : 938.1), 1126.0 (calc. for  $[M+5H]^{5+}$ : 1125.5), 1407.3 (calc. for 138  $[M+4H]^{4+}$ : 1406.7), 1876.0 (calc. for  $[M+3H]^{3+}$ : 1875.2).

#### 140 Section S1 – Supplementary Materials and Methods

141

#### 142 Microscale Thermophoresis (MST) experiments

To estimate the K<sub>D</sub> of the constructed 2D10-HL-DogTag and 3G12-HL-DogTag scFvs for 143 binding to RSV-G variants, purified scFvs were labeled with Alexa647 and used in MST binding 144 experiments. For labelling, the protein was concentrated using an Amicon filter (10 MWCO) and 145 buffer exchanged to 0.2 M sodium bicarbonate pH 8.3 using PD SpinTrap G-25 columns (Cytiva) 146 147 according to the manufacturer's protocol. 100  $\mu$ l of each protein at ~15  $\mu$ M was mixed with 10  $\mu$ l of Alexa-647 NHS Ester (Lumiprobe) freshly dissolved in DMSO (10 mg/ml) and incubated for 148 1 h at 22 °C with constant shaking. The reaction was purified from excess dyes by subsequently 149 applying it to PD SpinTrap G-25 column twice. The concentration of the protein and the efficiency 150 of labeling was calculated according to (2). Labelled scFvs were mixed with varying concentrations 151 of target and incubated for 1 h at 22 °C in a volume of 40 µl in 1xPBS & 0.02% Tween20 (final 152 153 scFv concentration 2 nM). Capillaries were loaded and MST experiment was performed at 60% LED power and 40% MST power on a Monolith NT.115 (NanoTemper Technologies). 154

#### 156 **ddPCR**

Viral RNA from virus samples was prepared for digital-droplet PCR (ddPCR) by adding an inactivation buffer (200 mM TCEP, 2 mM EDTA, 2 U/ $\mu$ l murine RNase inhibitor, 20 mM Tris-HCl, pH 8.0) to the sample in 1:1 ratio, followed by incubation at 95°C for 5 min. Subsequently, the 1-Step RT-ddPCR Advanced Kit for Probes (BioRad) was used in combination with the CFX96 thermocycler and the QX200 ddPCR system, using the following oligos and probes depending on the virus targeted. Data was analysed using BioRad QX One (v1.2). The oligos target the M gene of IAV and the M gene of RSV, respectively.

164 165

155

ddPCR oligo list	
IAV targeting oligos	sequences $(5' \rightarrow 3')$
FLUAM-7-F	CTTCTAACCGAGGTCGAAACGTA
FLUAM-161-R	GGTGACAAGATTGGTCTTGTCTTTA
FLUAM-49-P	TCAGGCCCCCTCAAAGCCGAG
RSV targeting oligos	
RSVM-F	GGCAAATATGGAAACATACGTGAA
RSVM-R	TCTTTTTCTAGGACATTGTATTGAACAG
RSVM-P	CTGTGTATGTGGAGCCTTCGTGAAG

166

#### 167 Influenza A virus and RSV sample collection from residual clinical materials

Patients were swabbed with eSwab (Copan, Italy) flocked tips, containing 1 ml of liquid 168 modified Amies fluid. Molecular diagnostics were performed using GeneXpert SARS-CoV-169 2/Flu/RSV rapid test (Cepheid, Sunnyvale, CA, USA), BioFire RP2.1plus rapid test (bioMérieux, 170 France), and Allplex RV Essential assay RT-PCR (Seegene, Seoul, South Korea) combined with 171 172 the FlowGO middle ware (LabHelp Labautomation, Bladel, the Netherlands) as previously described (3). Standard curves for correlating the ddRT-PCR experiments to GeneExpert and 173 Seegene Ct-values were obtained from dilution series of the A/swine/Italy/114922/2014 (H1N2) 174 and RSV-A2 stocks. 175

177	Section S2
178	Protein sequences
179	The used tags for protein purifications are hexa-His-tag (HHHHHH) and Strep-tag II
180	(WSHPQFEK).
181	
182	LgBiT-DogCatcher (LgBiT-Dog1):
183	Blue: LgBiT, Red: DogCatcher
184	MGTSVFTLEDFVGDWEQTAAYNLDQVLEQGGVSSLLQNLAVSVTPIQRIVRSGENALKI
185	DIHVIIPYEGLSADQMAQIEEVFKVVYPVDDHHFKVILPYGTLVIDGVTPNMLNYFGRPY
186	EGIAVFDGKKITVTGTLWNGNKIIDERLITPDGSMLFRVTINSSGGGTKLGEIEFIKVDKTD
187	KKPLRGAVFSLQKQHPDYPDIYGAIDQNGTYQDVRTGEDGKLTFTNLSDGKYRLIENSEP
188	PGYKPVQNKPIVSFRIVDGEVRDVTSIVPQGGGSWSHPQFEK*
189	
190	DogCatcher-SmBiT (SmBiT-Dog1):
191	Red: DogCatcher, yellow: SmBiT101 (4)
192	MGT <mark>KLGEIEFIKVDKTDKKPLRGAVFSLQKQHPDYPDIYGAIDQNGTYQDVRTGEDGKL</mark>
193	TFTNLSDGKYRLIENSEPPGYKPVQNKPIVSFRIVDGEVRDVTSIVPQGKLGGSGGSGGSG
194	GSGGSGGSGGSGGSGGENLYFQSGGSGGSGGSGGSGGSGGSGGSGGSGGTGS <mark>VTGYRLFEKE</mark>
195	SGGSGGSWSHPQFEK*
196	
197	SD36-DogTag:
198	Blue: SD36, green: DogTag.
199	MGSVQLVESGGGLVQAGGSLKLSCAASGRTYAMGWFRQAPGKEREFVAHINALGTRTY
200	YSDSVKGRFTISRDNAKNTEYLEMNNLKPEDTAVYYCTAQGQWRAAPVAVAAEYEFW
201	<mark>GQGTQVTVS</mark> GGSGGSGTGDIPATYEFTDGKHYITNEPIPPKGGSGGSWSHPQFEK*
202	
203	HSB2.A-DogTag:
204	Blue: HSB2.A, green: DogTag.
205	MGSHHHHHHSSG <mark>GIVNVPNCNTTKYQQLARTAVAIYNYHEQAHLTFVENLNCKEQGNY</mark>
206	YYITLAATDDAGKKAIYEAKIGVVESAGWTGVEEFKLVGSGGSGGSGGSGGSGGSGGSGGS
207	GSGTGDIPATYEFTDGKHYITNEPIPPKGGSGGSWSHPQFEK*
208	
209	SD38-DogTag:
210	Blue: SD38, green: DogTag.
211	MEVQLVESGGGLVQPGGSLRLSCAVSISIFDIYAMDWYRQAPGKQRDLVATSFRDGSTN
212	YADSVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYLCHVSLYRDPLGVAGGMGVYWG
213	KGALVTVSSKLGGSGGSGGSGGSGGSGGSTGDIPATYEFTDGKHYITNEPIPPKGGSGGSWSH
214	PQFEK*
215	
216	
217	F-VHH-4-DogTag:
218	Blue: F-VHH-4, green: DogTag
219	MGSQVQLQESGGGLVQPGGSLRLSCAASGFTLDYYYIGWFRQAPGKEREAVSCISGSSGS
220	TYYPDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCATIRSSSWGGCVHYGMDYW
221	GKGTQVTVSSKLGGSGGSGGSGGSGGSGGSGGSTGDIPATYEFTDGKHYITNEPIPPKGGSGGSWS
222	HPQFEK*
223	
224	LgBiT-3xDogCatcher (LgBiT-Dog3)
225	Blue: LgBiT, red: DogCatcher (3 times)

226	MGTSVFTLEDFVGDWEQTAAYNLDQVLEQGGVSSLLQNLAVSVTPIQRIVRSGENALKI
227	DIHVIIPYEGLSADQMAQIEEVFKVVYPVDDHHFKVILPYGTLVIDGVTPNMLNYFGRPY
228	EGIAVFDGKKITVTGTLWNGNKIIDERLITPDGSMLFRVTINGGSGELTGGSGGSGGSGGS
229	GGSGGSGEFAEAAAKEAAAKEAAAKEAAAKEAAAKEAAAKEAAAKAAEFGGSGGSGGSGGSGG
230	SGGSGGTKLGEIEFIK VDKTDKKPLRGAVESLOKOHPDYPDIYGAIDONGTYODVRTGED
231	GKI TETNI SDGK VRI IENSEPPGVK PVONK PIVSER IVDGEVR DVTSIVPOTSTPTPTPTP
231	ΤΡΤΡΤΡΤΡΤΡΤΡΤΡΤΡΤΡΤΡΤΡΤΡΤΡΤΡΤΡΤΡΤΡΛ SKI GEIEFIK VDK TDKK PI RGAVESI OKOHP
232	DVDDIVCA IDONCTVODVDTCEDCVI TETNI SDCVVDI JENSEDDCVVDVONVDIVSEDIV
233	
234	
235	VDKIDKKPLKGAVFSLQKQHPDIPDIIGAIDQNGIIQDVKIGEDGKLIFINLSDGKIKL
236	IENSEPPGYKPVQNKPIVSFKIVDGEVKDVISIVPQGGGSWSHPQFEK*
237	
238	3xDogCatcher-SmBiT (SmBiT-Dog3):
239	Red: DogCatcher (3 times), yellow: SmBiT101
240	MGTKLGEIEFIKVDKTDKKPLRGAVFSLQKQHPDYPDIYGAIDQNGTYQDVRTGEDGKL
241	<u>TFTNLSDGKYRLIENSEPPGYKPVQNKPIVSFRIVDGEVRDVTSIVPQTSTPTPTPTPTPTPT</u>
242	PTPTPTPTPTPTPTPTPTPTPTPTPTPAS <mark>KLGEIEFIKVDKTDKKPLRGAVFSLQKQHPDY</mark>
243	PDIYGAIDQNGTYQDVRTGEDGKLTFTNLSDGKYRLIENSEPPGYKPVQNKPIVSFRIVDG
244	EVRDVTSIVPQTGPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPT
245	KTDKKPLRGAVFSLQKQHPDYPDIYGAIDQNGTYQDVRTGEDGKLTFTNLSDGKYRLIE
246	NSEPPGYKPVQNKPIVSFRIVDGEVRDVTSIVPQGGGSGELTGGSGGSGGSGGSGGSGGSG
247	GEFAEAAAKEAAAKEAAAKEAAAKEAAAKEAAAKAEFGGSGGSGGSGGSGGSGGSGGSGG
248	T <mark>VTGYRLFEKES</mark> GGSHHHHHH*
249	
250	scFvs:
251	scFv sequences are listed in their secreted form, omitting the $\alpha$ -factor secretion signal present in
252	pPICZalphaB.
253	
254	AS4C-HL-DogTag
255	The original heavy and light chain sequences of the AS4C antibody were provided by Pramila Rijal
255	and Alan Townsend A heavy chain-light chain (HI) configuration scFy was designed based on
250	these sequences
257	Green: DogTag
250	EAEAAC(ASAC hogy) chain)CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
239	ATVEETDCVUVITNEDIDDVCCSCCSUUUUUU
200	ATTEFIDUKHTIINEFIFFKUUSUUSIIIIIIII
261	
262	IGOI-HL-DogTag:
263	Underlined: IGUI-HL, green: Dog1ag
264	EAEAAG <u>EVQLVESGGRALKPGGSLKLSCAASGFKFDDYAMSWVRQVPGKGLEFVSGLN</u>
265	WNGDITAY IDSVKGRFTVSRDNAKNSLYLHINSPKPEDTALYYCARTSSWGDYTRGPEP
266	<u>KITWYFDLWGRGTLVTVSSGGGGSGGGGGGGGGGGGGGGGGGGGGGGGGGG</u>
267	<u>QGIDGYLAWYQQRPGKAPNLLIYAASLLQSGVPSRFSGSGYGTEFTLTISSLQPEDFATYY</u>
268	<u>CQHLDSYPLFTFGPGTKVDIKRT</u> GTSGGGSGTGDIPATYEFTDGKHYITNEPIPPKGGSGG
269	SHHHHHH*
270	
271	2D10-HL-DogTag:
272	Underlined: 2D10-HL, green: DogTag
273	EAEAAGQVQLVQSGPEVKKPGASVRLSCKASGYVFTNYGVSWVRQAPGQGLEWMGWS
274	<u>SPYNGNTYYAQKLKARVTMTTDTSTNTAYMELRSLRSDDTAVYYCGRDMLGVVQAVA</u>
275	<u>GPFDSWGQGTLVTVSSASGGGGSGGGGGGGGGGGGGGGGGGGGGGGGGGGG</u>

## 276 <u>RASQGISNSLAWYQQKLGKAPQLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFA</u> 277 <u>TYYCQQTNTFPFTFGPGTKVEVRR</u>GTSGGGSGTGDIPATYEFTDGKHYITNEPIPPKGGSG

- 278 GSHHHHHH\*
- 279
- 280 3G12-HL-DogTag
- 281 Underlined: 3G12-HL, green: DogTag

- 288
- 289
- 290
- 291

#### 293 **References**

- 294
  295 1. A. Gräwe, C. M. Spruit, R. P. de Vries, M. Merkx, Bioluminescent detection of viral surface proteins using 296 branched multivalent protein switches. *RSC Chem Biol* 5, 148–157 (2024).
- J. S. Nanda, J. R. Lorsch, "Labeling a Protein with Fluorophores Using NHS Ester Derivitization" in *Methods in Enzymology*, J. R. Lorsch, Ed. (2014) vol. 536, pp. 87–94.
- 299 3. J. Flipse, A. T. Tromp, D. Thijssen, N. van Xanten-Jans-Beken, R. Pauwelsen, H. J. van der Veer, J. M.
- Schlaghecke, C. M. A. Swanink, Optimization of the STARlet workflow for semi-automatic SARS-CoV-2
   screening of swabs and deep respiratory materials using the RealAccurate Quadruplex SARS-CoV-2 PCR kit
   and Allplex SARS-CoV-2 PCR kit. *Microbiol Spectr* 12 (2024).
- 4. A. S. Dixon, M. K. Schwinn, M. P. Hall, K. Zimmerman, P. Otto, T. H. Lubben, B. L. Butler, B. F.
- Binkowski, T. MacHleidt, T. A. Kirkland, M. G. Wood, C. T. Eggers, L. P. Encell, K. V. Wood, NanoLuc
   Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. *ACS Chem Biol* 11, 400–408 (2016).
- 307